Drug Trial Radar · NCT04126200
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
208
Actual
Start
Oct 7, 2019
Primary completion
Apr 17, 2025
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Belantamab mafodotin will be administered.
GSK3174998Drug
GSK3174998 will be administered.
FeladilimabDrug
feladilimab will be administered.
NirogacestatDrug
Nirogacestat will be administered.
DostarlimabDrug
Dostarlimab will be administered.
IsatuximabDrug
Isatuximab will be administered.
LenalidomideDrug
Lenalidomide will be administered.
DexamethasoneDrug
Dexamethasone will be administered.
PomalidomideDrug
Pomalidomide will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Randomized Across Sub-studiesTime frame: Day 1
Locations
38 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Grand Rapids, Michigan
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Porto Alegre, Brazil
GSK Investigational Site
Salvador, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Lille, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Frankfurt, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Kiel, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Leeuwarden, Netherlands
GSK Investigational Site
Utrecht, Netherlands
GSK Investigational Site
Oslo, Norway
GSK Investigational Site
Gdansk, Poland
GSK Investigational Site
Katowice, Poland
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Lublin, Poland
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Badalona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
PamplonaNavarra, Spain
GSK Investigational Site
Pozuelo de AlarcOn Madr, Spain
GSK Investigational Site
Falun, Sweden
GSK Investigational Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.